References for: association

Full identifier: http://purl.org/np/RAJLJ8WuczC6uwrh7JfdKAEvqA8m-7bcSOdeAELOqKiCM#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial.
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:50:53.133Z